KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Aquestive Therapeutics (AQST) Receivables - Net (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Receivables - Net data on record, last reported at $17.8 million in Q4 2025.

  • For Q4 2025, Receivables - Net rose 141.87% year-over-year to $17.8 million; the TTM value through Dec 2025 reached $17.8 million, up 141.87%, while the annual FY2025 figure was $17.8 million, 141.87% up from the prior year.
  • Receivables - Net reached $17.8 million in Q4 2025 per AQST's latest filing, up from $11.8 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $19.2 million in Q2 2022 and bottomed at $4.3 million in Q2 2024.
  • Average Receivables - Net over 5 years is $10.4 million, with a median of $9.5 million recorded in 2022.
  • Peak YoY movement for Receivables - Net: soared 179.91% in 2021, then tumbled 61.19% in 2022.
  • A 5-year view of Receivables - Net shows it stood at $12.1 million in 2021, then crashed by 61.19% to $4.7 million in 2022, then soared by 80.08% to $8.5 million in 2023, then decreased by 13.3% to $7.3 million in 2024, then soared by 141.87% to $17.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Net were $17.8 million in Q4 2025, $11.8 million in Q3 2025, and $9.7 million in Q2 2025.